Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient

R Sarzani, G Laureti, A Gezzi… - … in Chronic Disease, 2022 - journals.sagepub.com
Arterial hypertension is one of the major causes of cardiovascular morbidity and mortality
worldwide. Effective and sustained reduction in blood pressure is essential to reduce …

Metabolic changes with the occurrence of atherosclerotic plaques and the effects of statins

L Zhao, D Ma, LJ Wang, XQ Su, LS Feng… - Frontiers in …, 2023 - frontiersin.org
Atherosclerosis is a common cardiovascular disease caused by the abnormal expression of
multiple factors and genes influenced by both environmental and genetic factors. The …

Synergistic hypolipidemic effects and mechanisms of phytochemicals: a review

Y Liu, C Liu, X Kou, Y Wang, Y Yu, N Zhen, J Jiang… - Foods, 2022 - mdpi.com
Hyperlipidemia, a chronic disorder of abnormal lipid metabolism, can induce obesity,
diabetes, and cardiovascular and cerebrovascular diseases such as coronary heart disease …

Crystal structure of mRNA cap (guanine-N7) methyltransferase E12 subunit from monkeypox virus and discovery of its inhibitors

DP Wang, R Zhao, HF Wang, MY Wang, WS Hu… - International Journal of …, 2023 - Elsevier
Abstract In July 2022, the World Health Organization announced monkeypox as a public
health emergency of international concern (PHEIC), and over 85,000 global cases have …

Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation

J Moon, SY Lee, HS Na, AR Lee, KH Cho… - Frontiers in …, 2022 - frontiersin.org
Ankylosing spondylitis (AS) is a chronic inflammatory disease that causes spinal
inflammation and fusion. Although the cause of AS is unknown, genetic factors (eg, HLA …

Dyslipidemia treatment and lipid control in US adults with diabetes by sociodemographic and cardiovascular risk groups in the NIH Precision Medicine Initiative All of …

M Akbarpour, D Devineni, Y Gong… - Journal of clinical medicine, 2023 - mdpi.com
Real-world data on lipid levels and treatment among adults with diabetes mellitus (DM) are
relatively limited. We studied lipid levels and treatment status in patients with DM across …

[HTML][HTML] Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?

E Domingo, P Marques, V Francisco, L Piqueras… - Pharmacological …, 2024 - Elsevier
Cardiovascular disease (CVD) remains the leading cause of death and disability worldwide.
While many factors can contribute to CVD, atherosclerosis is the cardinal underlying …

Recent advances on quinoxalines as target‐oriented chemotherapeutic anticancer agents through apoptosis

MS Nafie, SH Kahwash, MM Youssef… - Archiv der …, 2024 - Wiley Online Library
The current review outlines all possible recent synthetic platforms to quinoxaline derivatives
and the potent stimulated apoptosis mechanisms targeted by anticancer therapies. The …

Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

JM Mostaza, C Escobar - Journal of Clinical Medicine, 2024 - mdpi.com
Vascular diseases are the leading cause of death in Spain. Hypercholesterolemia is not only
a cardiovascular risk factor, but also underlies the etiopathogenesis of atherosclerosis …

Strategic design and clinical evaluation of a fixed-dose combination tablet comprising valsartan, amlodipine, rosuvastatin and ezetimibe for patients with hypertension …

TK Kim, JE Lee, K Jeong, MJ Baek, D Kim… - Journal of …, 2024 - Springer
Purpose The objective of this study was to design a fixed-dose combination (FDC) tablet
with minimal interaction of valsartan, amlodipine, rosuvastatin and ezetimibe to improve …